      |
 |
 |
THE FACULTY AND THEIR RESEARCH
David S. Alberts, Professor, M.D., University of Virginia, 1966Phase I and clinical pharmacokinetics of cancer chemotherapeutic and cancer prevention agents; drug interactions; clinical pharmacology; in vitro drug assay and biomarker studies in tumor cells; cancer chemopreventive agent pharmacology; and drug development trials.
H. Vasken Aposhian, Professor, Ph.D., University of Rochester ,New York, 1953Molecular mechanisms and treatment of heavy metal intoxication; therapeutic chelating agents. William T. Bellamy, Associate Professor, Ph.D., University of Arizona, 1988Cancer pharmacology with an emphasis on tumor angiogenesis as well as the mechanisms responsible for drug resistance; in vitro and in vivo reversal of drug resistance; in situ hybridization.
John W. Bloom, Professor, M.D., Jefferson University, 1971Molecular mechanisms of glucocorticoid action in the lung; mechanisms of eosinophil apoptosis; effects of genetic polymorphisms on gene expression in asthma.
G. Timothy Bowden, Professor, Ph.D., University of Wisconsin-Madison, 1974Molecular aspects of chemical and physical carcinogenesis; mechanisms of oncogene activation and signal transduction pathways.
Margaret M. Briehl, Assistant Professor, Ph.D., University of Arizona, 1988Relationship between oxidative stress, apoptosis, and the development of cancer.
Janis M. Burt, Professor ; Ph.D., University of California - Irvine, 1980Mechanisms controlling intercellular signaling via gap junctions in the cardiovascular system; role of gap junctions in growth control,response to injury, cardiac arrhythmias and vascular disease. Dean E. Carter, Professor, Ph.D., University of Arizona, 1969Analytical toxicology; pharmacokinetic studies in animals and humans; toxicity of metals used in the electronics industry.
Qin M. Chen, Associate Professor, Ph.D., Clarkson University, New York, 1991Molecular mechanisms of oxidative injury and adaptation, stress signal transduction pathways, stress gene expression, senescence, apoptosis and cardiac hypertrophy. Thomas P. Davis, Professor, Ph.D., University of Missouri, 1978Neuropharmacology; molecular regulation of growth factor processing and metabolism; biotech approaches to targeting the blood-brain barrier for new drug development; effects of hypoxia, aglycemia, stroke, peripheral pain and nicotine on endothelial cell permeability, resistance and cytoarchitecture.
Robert T. Dorr, Professor, Ph.D., University of Arizona, 1984Toxicology systems and mechanisms of action of cytotoxic anticancer agents; the pharmacology of cancer chemopreventive agents. Edward D. French, Professor, Ph.D., UCLA, 1979Neuropharmacology of drugs of abuse, using electrophysiological and behavioral endpoints; application to models of schizophrenia.
Bernard W. Futscher, Associate Professor, Ph.D., Loyola University, Chicago, 1990Functional genomics; molecular biology of cancer; cancer pharmacology. A. Jay Gandolfi, Professor, Ph.D., Oregon State University, 1972Bioactivation of xenobiotics: in vitro toxicology systems; renal/hepatic toxicology; toxicity of halogenated hydrocarbons, and metals; mechanisms cell injury. Marilyn J. Halonen, Professor, Ph.D., University of Arizona, 1974Immunopharmacology; alterations in cytokine regulation of IgE levels; cell biology of naturally occurring polymorphisms in cytokine genes related to asthma or allergy in humans; immune response development in infancy in relation to respiratory viruses and allergens.
Laurence H. Hurley, Professor, Ph.D., Purdue University, 1970Discovery and development of novel anticancer drugs; telomeres; telomerase; transcriptional control; topoisomerases as drug targets. Elaine L. Jacobson, Professor, Ph.D., Kansas State University, 1971Optimizing molecular and cellular responses to UV radiation in skin; inhibition of advanced glycation end-products; DNA damage and repair.
Myron K.. Jacobson, Professor, Ph.D., Kansas State University, 1970Molecular mechanisms involved in maintenance of genomic integrity. Josephine Lai, Professor, Ph.D., Imperial College, London, 1985Molecular mechanisms of neuropathic pain; opioid receptor pharmacology; gene targeting; drug discovery.
R. Clark Lantz, Professor, Ph.D., University of West Virginia, 1975Pulmonary toxicology of air pollutants, especially metals; effects of air pollutants on neonatal lung growth and development.
Douglas F. Larson, Associate Professor, Ph.D., University of Arizona, 1984Immunopharmacology: pharmacology and design of selective immunosuppressive therapies for solid organ transplantation and auto-immune diseases.
Ronald J. Lukas, Research Professor, Ph.D., SUNY, Downstate Medical Center, 1976Nicotinic acetylcholine receptor biology using clonal cell lines and transgene expression systems; neurotrophic factors; neurodegenerative diseases; neuronal differentiation.
Ronald M. Lynch, Associate Professor, Ph.D., University of Cincinnati, 1984Hypertension, diabetes, and obesity; endocrine pharmacology and metabolism; excitability in cells of the pancreas hypothalamic neurons and the vasculature; microscopic spectroscopy and imaging. T. Philip Malan, Jr., Professor, Ph.D. Harvard University, 1981, M.D. 1985Neuropharmacy; pharmacology and molecular biology of neuropathic pain.
Michael Mayersohn, Professor, Ph.D., SUNY, Buffalo, 1970Pharmacokinetics and toxicokinetics; drugs of abuse; in vitro-in vivo metabolism; pharmacodynamics.
Paul F. McDonagh, Professor, Ph.D., University of California, Davis, 1976Cardiac protection; blood-blood vessel interactions in the etiology of ischemia-reperfusion injury.
Charlene A. McQueen, Professor, Ph.D., Michigan State University, 1978Pharmaco/toxicogenetics: mechanisms of chemical carcinogenesis; in vitro toxicology.
Bradley S. Moore, Assistant Professor, Ph.D., University of Washington, 1994Natural products biosynthesis; combinatorial biology; marine Streptomyces genetics; symbiosis; drug discovery.
Eugene Morkin, Professor of Medicine, M.D., University of Oklahoma, 1959Molecular basis for cardiac development and contractile function. Mark A. Nelson, Associate Professor, Ph.D., Washington State University, 1989Molecular mechanisms of carcinogenesis, biochemical and molecular pharmacology of anti-cancer drugs. Claire M. Payne, Research Professor, Ph.D., SUNY, Stony Brook, 1971Mechanisms of apoptosis in the immune system; role of apoptosis in tumorigenesis; mechanisms of cell death induced by pharmacologic/toxicologic agents.
Frank Porreca, Professor, Ph.D., Temple University, 1982Neurobiology of pain.
Garth Powis, Professor, D. Phil., University of Birmingham (England), 1967, D. Phil., Oxford University, 1970Intracellular signaling pathways that mediate the effects of growth factors and oncogenes in cancer cells. John W. Regan, Associate Professor, Ph.D., University of Arizona, 1981Molecular pharmacology of G-protein-coupled receptors: use of cloning, mutagenesis and expression to study receptor structure and the interaction of receptors with second messenger systems.
William R. Roeske, Professor, M.D., Stanford University, 1970Cardiovascular pharmacology; regulation, characterization, and identification of autonomic receptors; neuropharmacology of drugs of abuse. I. Glenn Sipes, Professor, Ph.D., University of Pennsylvania, 1969Mechanism of tissue injury induced by drugs or other xenobiotics; mechanisms by which one chemical modulates the toxicity of another; carcinogenesis, human metabolism of environmental pollutants.
Robert S. Sloviter, Professor, Ph.D., Pennsylvania State University, 1978Neuropharmacology, neurotoxicology, neuroanatomy, and neurophysiology of epilepsy and other neurological disorders; mechanisms of neuronal death; anticonvulsant drug mechanisms.
W. Daniel Stamer, Assistant Professor, Ph.D., University of Arizona , 1996Molecular and cellular mechanisms that underlie the regulation of aqueous humor outflow in the human eye; including receptor activation, second messenger signaling, ion and water transport, and secretory function. Barbara N. Timmermann, Professor, Ph.D., University of Texas, 1980Natural products chemistry; biodiversity prospecting for drug discovery; antioxidant chemistry; catechins in cancer prevention. Richard R. Vaillancourt, Assistant Professor, Ph.D., University of Wisconsin, Madison, 1992Molecular and biochemical characterization of serine/threonine protein kinases that function as part of sequential protein kinase pathways.
Todd W. Vanderah, Assistant Professor, Ph.D., University of Arizona, 1995Mechanisms and pharmacology of acute and chronic models of pain; endogenous opioid systems; sensory neural systems; opioid tolerance; antinociceptive synergy between cannabinoids and opioids. Mark L. Witten, Research Associate Professor, Ph.D., Indiana State University, 1983Acute and chronic exposure to environmental toxins and their effect on the pulmonary system, including host cellular defense system. Henry I. Yamamura, Regent's Professor, Ph.D., University of Washington, Seattle, 1969Neuropharmacology; mechanism of psychotropic drugs in the CNS; molecular biology of neurotransmitter and drug receptors; second messenger coupling with receptors.
Danzhou Yang, Assistant Professor, Ph.D., University of Illinois, Urbana 1996 .Targeting interactions of anti-cancer drugs and rational drug design. Andrea J. Yool, Associate Professor, Ph.D., University of California, Santa Barbara, 1985Viral-mediated gene therapy for ion channel disorders in CNS and skeletal muscle; Molecular mechanisms of ion channel function in Aquaporins.
|